December 4th 2024
EXO Biologics and ExoXpert, an EXO Biologics subsidiary, have received GMP certification of a European manufacturing facility for exosomes and have successfully loaded mRNA and DNA payloads into GMP-grade exosomes for drug delivery.
The evolution of therapeutic modalities drives the adoption of single-use technologies.
Using Receptor Architecture to Improve CAR-T Cell Sensitivity in Oncology (ASGCT 2024)
May 11th 2024Phillip Gregory, PhD, senior vice-president and head of Regeneron Cell Medicines, Regeneron, discussed how engineering receptor architecture can be a tool to improve CAR-T cell sensitivity to tumor antigens.
INTERPHEX 2024: Implementing Contamination Control Strategies in Cell and Gene Therapy Facilities
April 22nd 2024A panel of experts went over new regulatory requirements for contamination control and gave guidance on implementing a contamination control strategy in cell and gene therapy facilities at INTERPHEX 2024.